Compile Data Set for Download or QSAR
Report error Found 67 Enz. Inhib. hit(s) with all data for entry = 11513
Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621998BDBM621998(US20230312542, Example 54)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621993BDBM621993(US20230312542, Example 44)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622037BDBM622037(US20230312542, Example 159)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622021BDBM622021(US20230312542, Example 107)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622022BDBM622022(US20230312542, Example 108)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622023BDBM622023(US20230312542, Example 111)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622033BDBM622033(US20230312542, Example 153)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622034BDBM622034(US20230312542, Example 154)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622036BDBM622036(US20230312542, Example 158)
Affinity DataKd: <1.00E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622029BDBM622029(US20230312542, Example 144)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622031BDBM622031(US20230312542, Example 148)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622032BDBM622032(US20230312542, Example 150)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622026BDBM622026(US20230312542, Example 139)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622027BDBM622027(US20230312542, Example 140)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622028BDBM622028(US20230312542, Example 141)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621974BDBM621974(US20230312542, Example 1)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621975BDBM621975(US20230312542, Example 6)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621976BDBM621976(US20230312542, Example 14)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622035BDBM622035(US20230312542, Example 155)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622013BDBM622013(US20230312542, Example 84)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622014BDBM622014(US20230312542, Example 89)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622015BDBM622015(US20230312542, Example 90)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622016BDBM622016(US20230312542, Example 91)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622009BDBM622009(US20230312542, Example 78)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622010BDBM622010(US20230312542, Example 79)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622011BDBM622011(US20230312542, Example 80)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622012BDBM622012(US20230312542, Example 81)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622024BDBM622024(US20230312542, Example 112)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622017BDBM622017(US20230312542, Example 93)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622019BDBM622019(US20230312542, Example 97)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621997BDBM621997(US20230312542, Example 53)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621999BDBM621999(US20230312542, Example 61)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622000BDBM622000(US20230312542, Example 62)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621994BDBM621994(US20230312542, Example 48)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621995BDBM621995(US20230312542, Example 49)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621996BDBM621996(US20230312542, Example 51)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622006BDBM622006(US20230312542, Example 74)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622007BDBM622007(US20230312542, Example 75)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622008BDBM622008(US20230312542, Example 76)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622001BDBM622001(US20230312542, Example 63)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 622002BDBM622002(US20230312542, Example 64)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621981BDBM621981(US20230312542, Example 19)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621982BDBM621982(US20230312542, Example 20)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621983BDBM621983(US20230312542, Example 21)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621984BDBM621984(US20230312542, Example 22)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621977BDBM621977(US20230312542, Example 15)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621978BDBM621978(US20230312542, Example 16)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621979BDBM621979(US20230312542, Example 17)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621980BDBM621980(US20230312542, Example 18)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Targetvon Hippel-Lindau disease tumor suppressor(Human)
Mitsubishi Tanabe Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 621989BDBM621989(US20230312542, Example 30)
Affinity DataKd:  5.50E+3nMAssay Description:As the device, Biacore T200 (manufactured by GE Healthcare) was used. VHL was obtained by co-expressing Elongin B and Elongin C with a Twin-Strep-tag...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Displayed 1 to 50 (of 67 total ) | Next | Last >>
Jump to: